

January 19, 2017

For Immediate Release

Company name Otsuka Holdings Co., Ltd.
Representative Tatsuo Higuchi
President and Representative Director, CEO
Code number 4578 First Section , Tokyo Stock Exchange
Inquiries Yuji Kogure
Director, Investors Relations Department

**Otsuka Receives Approval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti[®] Tablets for Schizophrenia**

Otsuka Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets[®] (generic name is brexpiprazole) in 1mg and 2 mg dosage sizes.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT_{1A} and dopamine D₂ receptors, and an antagonist at 5-HT_{2A} and noradrenaline alpha_{1B/2C} receptors.